Gene:
ADD1
adducin 1 (alpha)

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for ADD1

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs4961 NC_000004.11:g.2906707G>T, NC_000004.12:g.2904980G>T, NG_012037.1:g.66124G>T, NM_001119.4:c.1378G>T, NM_001286645.1:c.1378G>T, NM_014189.3:c.1378G>T, NM_014190.3:c.1378G>T, NM_176801.2:c.1378G>T, NP_001110.2:p.Gly460Trp, NP_001273574.1:p.Gly460Trp, NP_054908.2:p.Gly460Trp, NP_054909.2:p.Gly460Trp, NP_789771.1:p.Gly460Trp, XM_005247933.1:c.1378G>T, XM_005247934.1:c.1378G>T, XM_005247935.1:c.1378G>T, XM_005247936.1:c.1378G>T, XM_005247937.1:c.1378G>T, XM_005247938.1:c.1378G>T, XP_005247990.1:p.Gly460Trp, XP_005247991.1:p.Gly460Trp, XP_005247992.1:p.Gly460Trp, XP_005247993.1:p.Gly460Trp, XP_005247994.1:p.Gly460Trp, XP_005247995.1:p.Gly460Trp, rs113752720, rs52823896, rs61347248
G > T
SNP
G460W
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA31

Details

Cytogenetic Location: chr4 : p16.3 - p16.3
GP mRNA Boundary: chr4 : 2845454 - 2931803
GP Gene Boundary: chr4 : 2835454 - 2934803
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Diuretics Pathway, Pharmacodynamics
    Diagrammatic representation of candidate genes involved in the pharmacodynamics of thiazide diuretics, loop diuretics and potassium-sparing diuretics in a stylized kidney cell.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ATP1A1

Curated Information ?

Curated Information ?

Publications related to ADD1: 26

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension pharmacogenomics: in search of personalized treatment approaches. Nature reviews. Nephrology. 2015. Cooper-DeHoff Rhonda M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites. Clinical science (London, England : 1979). 2011. Yang Ying-Ying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics. 2011. Citterio Lorena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The genetics of loop diuretic effects. The pharmacogenomics journal. 2010. Vormfelde S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of antihypertensive drugs: past, present and future. Pharmacogenomics. 2010. Johnson Julie A. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. American journal of hypertension. 2009. van Rijn-Bikker Petra C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. American journal of hypertension. 2009. Suonsyrjä Timo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of hypertension. 2009. van Wieren-de Wijer Diane B M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). American heart journal. 2008. Gerhard Tobias, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension. 2008. Manunta Paolo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Diuretic-gene interaction and the risk of myocardial infarction and stroke. The pharmacogenomics journal. 2007. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adducin polymorphisms and the treatment of hypertension. Pharmacogenomics. 2007. Manunta Paolo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. The pharmacogenomics journal. 2007. Davis B R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics. 2006. Dervieux Thierry, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. European journal of human genetics : EJHG. 2006. Schelleman Hedi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. European journal of clinical pharmacology. 2006. Vormfelde Stefan Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular risk in relation to alpha-adducin Gly460Trp polymorphism and systolic pressure: a prospective population study. Hypertension. 2005. Li Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations of baseline blood pressure levels and efficacy of Benazepril treatment with interaction of alpha-adducin and ACE gene polymorphisms in hypertensives. Clinical and experimental hypertension (New York, N.Y. : 1993). 2005. Yu Yunxian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertension research : official journal of the Japanese Society of Hypertension. 2004. Matayoshi Tetsutaro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antihypertensive drug responses. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2004. Schwartz Gary L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. American journal of hypertension. 2003. Turner Stephen T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension. 2003. Sciarrone Maria Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA : the journal of the American Medical Association. 2002. Psaty Bruce M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension. 2002. Glorioso Nicola, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension. 1999. Glorioso N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997. Cusi D, et al. PubMed

LinkOuts

NCBI Gene:
118
OMIM:
102680
145500
UCSC Genome Browser:
NM_001119
RefSeq RNA:
NM_001119
NM_014189
NM_014190
NM_176801
RefSeq Protein:
NP_001110
NP_054908
NP_054909
NP_789771
RefSeq DNA:
NG_012037
NT_006051
UniProtKB:
A2A3N8_HUMAN (A2A3N8)
ADDA_HUMAN (P35611)
Ensembl:
ENSG00000087274
GenAtlas:
ADD1
GeneCard:
ADD1
MutDB:
ADD1
ALFRED:
LO000596U
HuGE:
ADD1
Comparative Toxicogenomics Database:
118
ModBase:
P35611
HumanCyc Gene:
HS01571
HGNC:
243

Common Searches